Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand amends XOMA Royalty merger agreement to add holding company HoldCo as a party

Neutral Impact 4 of 5 m&a Written later

Ligand Pharmaceuticals disclosed that on May 16, 2026 it, XOMA Royalty and its merger subsidiary signed Amendment No. 1 to the merger agreement first announced April 27, 2026. The amendment adds XOMA Royalty Holdings Corporation (HoldCo) as a party, which is tied to a holding company reorganization in which HoldCo would become a wholly owned Ligand subsidiary. The filing does not state a deal value or new terms beyond this change.

Key points

  • Merger Agreement with XOMA Royalty Corporation first entered into on April 27, 2026
  • Amendment No. 1 dated May 16, 2026 adds HoldCo as a party to the agreement
  • HoldCo will survive the merger as a wholly owned subsidiary of Ligand, following a holding company reorganization under Nevada law
  • XOMA Royalty stockholder approval and regulatory approvals are among the conditions to closing

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECMay 18, 2026, 9:01 AM ET
Accession number0001193125-26-228003

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.